Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: Update of the Literature

S Wolking, E Schaeffeler, H Lerche, M Schwab… - Clinical …, 2015 - Springer
ATP-binding cassette transporter B1 (ABCB1; P-glycoprotein; multidrug resistance protein 1)
is an adenosine triphosphate (ATP)-dependent efflux transporter located in the plasma …

Metformin and cancer: from the old medicine cabinet to pharmacological pitfalls and prospects

AE Riedmaier, P Fisel, AT Nies, E Schaeffeler… - Trends in …, 2013 - cell.com
Metformin is a biguanide derivative used in the treatment of type II diabetes (T2D) and one
of the world's most widely prescribed drugs. Owing to its safety profile, it has been recently …

Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing

A Teml, E Schaeffeler, KR Herrlinger, U Klotz… - Clinical …, 2007 - Springer
This review summarises clinical pharmacological aspects of thiopurines in the treatment of
chronic inflammatory bowel disease (IBD). Current knowledge of pharmacogenetically …

Frequency of single nucleotide polymorphisms in the P‐glycoprotein drug transporter MDR1 gene in white subjects

…, S Hoffmeyer, M Schwab, E Schaeffeler… - Clinical …, 2001 - Wiley Online Library
Background P‐glycoprotein, the gene product of MDR1, confers multidrug resistance against
antineoplastic agents but also plays an important role in the bioavailability of common …

Reduced Paneth cell α-defensins in ileal Crohn's disease

…, RE Petras, B Shen, E Schaeffeler… - Proceedings of the …, 2005 - National Acad Sciences
The pathogenesis of Crohn′s disease (CD), an idiopathic inflammatory bowel disease, is
attributed, in part, to intestinal bacteria that may initiate and perpetuate mucosal inflammation …

A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study

…, V Rollinson, R Roncato, M Samwald, E Schaeffeler… - The Lancet, 2023 - thelancet.com
Background The benefit of pharmacogenetic testing before starting drug therapy has been
well documented for several single gene–drug combinations. However, the clinical utility of a …

[PDF][PDF] A chromosome 8 gene-cluster polymorphism with low human beta-defensin 2 gene copy number predisposes to Crohn disease of the colon

K Fellermann, DE Stange, E Schaeffeler… - The American Journal of …, 2006 - cell.com
Defensins are endogenous antimicrobial peptides that protect the intestinal mucosa against
bacterial invasion. It has been suggested that deficient defensin expression may underlie …

[PDF][PDF] Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group

…, UM Zanger, C Marx, E Schaeffeler… - Journal of clinical …, 2008 - academia.edu
Purpose To assess the predictive value of polymorphisms in dihydropyrimidine dehydrogenase
(DPYD), thymidylate synthase (TYMS), and methylene tetrahydrofolate reductase (…

Comprehensive analysis of thiopurine S-methyltransferase phenotype–genotype correlation in a large population of German-Caucasians and identification of novel …

E Schaeffeler, C Fischer, D Brockmeier… - Pharmacogenetics …, 2004 - journals.lww.com
The thiopurine S-methyltransferase (TPMT) genetic polymorphism has a significant clinical
impact on the toxicity of thiopurine drugs. It has been proposed that the identification of …

High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C …

M Niemi, E Schaeffeler, T Lang… - Pharmacogenetics …, 2004 - journals.lww.com
This study aimed to characterize possible relationships between polymorphisms in the drug
transporter genes organic anion transporting polypeptide-C (OATP-C, SLCO1B1), OATP-B (…